Bildkälla: Stockfoto

BioInvent: Positive Interim Readout of BI-1808 - Redeye

Redeye comments on the positive readout from the phase I/IIa trial with the anti-TNFR2 antibody BI-1808 in advanced cancer.

Redeye comments on the positive readout from the phase I/IIa trial with the anti-TNFR2 antibody BI-1808 in advanced cancer.
Börsvärldens nyhetsbrev
ANNONSER